Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
260 hedge funds and large institutions have $4.04B invested in Apellis Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 98 increasing their positions, 72 reducing their positions, and 63 closing their positions.
212% more call options, than puts
Call options by funds: $104M | Put options by funds: $33.5M
36% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 72
19% more capital invested
Capital invested by funds: $3.41B → $4.04B (+$635M)
4.82% more ownership
Funds ownership: 97.05% → 101.87% (+4.8%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
3% less first-time investments, than exits
New positions opened: 61 | Existing positions closed: 63
2% less funds holding
Funds holding: 265 → 260 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$188M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$68.3M |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$41.7M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$41.4M |
| 5 |
CWM
CIBC World Markets
New York
|
+$38.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$113M |
| 2 |
JP Morgan Chase
New York
|
-$104M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$88.3M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$63.6M |
| 5 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$39.1M |
APLS Hedge Fund Activity: Q4 2024 in Review
260 of the 7,599 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q4 2024, worth a combined $4.04B — up 19% from $3.41B a quarter earlier.
Sellers outnumbered buyers: 63 funds closed out of APLS and 61 opened new positions — a net loss of 2 holders — while 72 trimmed existing stakes and 98 added.
The largest buyer was Morgan Stanley, adding an estimated $188M. The largest seller was Wellington Management Group, cutting an estimated $113M.
- 260 institutional investors held Apellis Pharmaceuticals (APLS) as of Q4 2024, down from 265 in Q3 2024.
- Funds reported $4.04B of Apellis Pharmaceuticals stock for Q4 2024, up 19% quarter-over-quarter.
- 61 funds opened new Apellis Pharmaceuticals positions in Q4 2024 and 63 closed out, a net change of -2 holders.
- The largest Apellis Pharmaceuticals buyer in Q4 2024 was Morgan Stanley, an estimated $188M added.
- The largest Apellis Pharmaceuticals seller in Q4 2024 was Wellington Management Group, an estimated $113M sold.
Based on aggregated 13F filings for Q4 2024.